Ann: G Medical seeks delisting to pursue Q4 NASDAQ listing, page-506

Yes. All valid points.

As discussed myself and MG can easily support valuations around the $150m market. So I don't think it's a hard story to sell. See previous posts.

I can't imagine Yacov and the BOD would be going down this path unless they are very confident. By this I mean investors could already be lined up and or a portion of the deal could be underwriten by Fuson and Boustead.

One thing that hasn't been discussed is what happens to the OTC listing? Does it remain active and if so they may provide some limited liquidity. Could easy manipulate that price up to suit the Nasdaq listing...